Zobrazeno 1 - 10
of 267
pro vyhledávání: '"Yuhchyau Chen"'
Autor:
Sara J. Hardy, Sanjukta Bandyopadhyay, Hongmei Yang, Annalynn Williams, Abdi Gudina, Michael A. Cummings, Hong Zhang, Deepinder P. Singh, Yuhchyau Chen, Nimish A. Mohile, Michelle C. Janelsins, Michael T. Milano
Publikováno v:
Frontiers in Oncology, Vol 13 (2023)
ObjectivesHead and neck cancer is a common malignancy frequently treated with chemotherapy and radiotherapy. Studies have shown an increased risk of stroke with the receipt of radiotherapy, but data on stroke-related mortality are limited, particular
Externí odkaz:
https://doaj.org/article/548484f1f10c4b53b9072614ef7ec642
Autor:
Dong Chen, Fu-Ju Chou, Yuhchyau Chen, Chi-Ping Huang, Hao Tian, Yaqin Wang, Yuanjie Niu, Bosen You, Shuyuan Yeh, Nianzeng Xing, Chawnshang Chang
Publikováno v:
Journal of Experimental & Clinical Cancer Research, Vol 41, Iss 1, Pp 1-12 (2022)
Abstract Background Radiation therapy (RT) with androgen deprivation therapy (ADT) is an effective therapy to suppress the locally advanced prostate cancer (PCa). However, we unexpectedly found that RT could also induce the androgen receptor splice v
Externí odkaz:
https://doaj.org/article/4dac9b102b7147abafd5b1e546ebce3b
Autor:
Hong Zhang, Hongmei Yang, Sanjukta Bandyopadhyay, Michael T. Milano, Chunkit Fung, Edward M. Messing, Yuhchyau Chen
Publikováno v:
PLoS ONE, Vol 17, Iss 2 (2022)
Introduction Testicular cancer survivors (TCS) have an increased risk of additional cancers, including prostate cancer. Our understanding of the natural history of prostate cancer in testicular cancer survivors is very limited due to its rare inciden
Externí odkaz:
https://doaj.org/article/c2484c7e39bb4de5879cb9767f5ff98f
Autor:
Fu-Ju Chou, Yuhchyau Chen, Dong Chen, Yuanjie Niu, Gonghui Li, Peter Keng, Shuyuan Yeh, Chawnshang Chang
Publikováno v:
EBioMedicine, Vol 40, Iss , Pp 504-516 (2019)
Background: While androgen deprivation therapy (ADT) and radiotherapy (RT) are currently used together to treat locally advanced prostate cancer (PCa), RT might have the adverse effect of increasing the PCa androgen receptor (AR) protein expression,
Externí odkaz:
https://doaj.org/article/c1c2d45ea15a4b80a5f75b98f8fe4115
Autor:
Yuhchyau Chen, Fuquan Zhang, Ying Tsai, Xiadong Yang, Li Yang, Shanzhou Duan, Xin Wang, Peter Keng, Soo Ok Lee
Publikováno v:
Radiation Oncology, Vol 17, Iss 1, Pp 1-1 (2022)
Externí odkaz:
https://doaj.org/article/7bbc1ea3ec28409fb991f126628dfc7d
Autor:
Rahul Khairnar, Stephanie L Pugh, Howard M Sandler, W Robert Lee, Ester Villalonga Olives, C Daniel Mullins, Francis B Palumbo, Deborah W Bruner, Fadia T Shaya, Soren M Bentzen, Amit B Shah, Shawn C Malone, Jeff M Michalski, Ian S Dayes, Samantha A Seaward, Michele Albert, Adam D Currey, Thomas M Pisansky, Yuhchyau Chen, Eric M Horwitz, Albert S DeNittis, Felix Y Feng, Mark V Mishra
Publikováno v:
PLoS ONE, Vol 16, Iss 4, p e0249123 (2021)
PurposeThe Expanded Prostate Cancer Index Composite (EPIC) is the most commonly used patient reported outcome (PRO) tool in prostate cancer (PC) clinical trials, but health utilities associated with the different health states assessed with this tool
Externí odkaz:
https://doaj.org/article/28c81274f9f04bb1953d4d523b5584d0
Autor:
Hong Zhang, Christopher Doucette, Hongmei Yang, Sanjukta Bandyopadhyay, Craig E Grossman, Edward M Messing, Yuhchyau Chen
Publikováno v:
PLoS ONE, Vol 16, Iss 7, p e0253936 (2021)
BackgroundIntermediate risk prostate cancer represents a largely heterogeneous group with diverse disease extent. We sought to establish rates of adverse pathological features important for radiation planning by analyzing surgical specimens from men
Externí odkaz:
https://doaj.org/article/28a042af608a4af8a9c3b03eeff01d18
Autor:
William F. Regine, MD, Kathryn Winter, MS, Ross A. Abrams, MD, Howard Safran, MD, Ivan L. Kessel, MD, Yuhchyau Chen, MD, PhD, James A. Fugazzi, MD, Eric D. Donnelly, MD, Thomas A. DiPetrillo, MD, Samir Narayan, MD, John P. Plastaras, MD, Rakesh Gaur, MD, Guila Delouya, MD, John H. Suh, MD, Joshua E. Meyer, MD, Michael G. Haddock, MD, Mukund S. Didolkar, MD, Gilbert D.A. Padula, MD, David Johnson, MD, John P. Hoffman, MD, Christopher H. Crane, MD
Publikováno v:
Advances in Radiation Oncology, Vol 3, Iss 2, Pp 154-162 (2018)
Purpose: NRG Oncology RTOG 9704 was the first adjuvant trial to validate the prognostic value of postresection CA19-9 levels for survival in patients with pancreatic carcinoma. The data resulting from this study also provide information about predict
Externí odkaz:
https://doaj.org/article/7807a6dd9b14475d9809d5afcb59b0df
Autor:
LiJun Xu, XiaoDong Chen, MingJing Shen, Dong‐Rong Yang, Laifu Fang, Guobin Weng, Ying Tsai, Peter C. Keng, Yuhchyau Chen, Soo Ok Lee
Publikováno v:
Molecular Oncology, Vol 12, Iss 3, Pp 269-286 (2018)
To investigate whether IL‐6 signaling affects the susceptibility of castration‐resistant prostate cancer (CRPC) cells to cytotoxic action of natural killer (NK) cells, CRPC cell lines (having different IL‐6 levels) were developed by lentiviral
Externí odkaz:
https://doaj.org/article/0e1b38ca22934efe8f176cd3c35dcb5c
Autor:
Li Yang, MingJing Shen, Li Jun Xu, Xiaodong Yang, Ying Tsai, Peter C. Keng, Yuhchyau Chen, Soo Ok Lee
Publikováno v:
Scientific Reports, Vol 7, Iss 1, Pp 1-13 (2017)
Abstract Major progress has been made clinically in inhibiting the programmed death receptor 1 (PD-1)/PD-L1 interaction to enhance T cell-mediated immune function, yet the effectiveness of anti-PD-L1/PD-1 agents in enhancing natural killer (NK) cell
Externí odkaz:
https://doaj.org/article/c269617aaab84a4390a2877858fd746b